A major regulatory achievement has been reached in the progression of a next-generation RNAi therapy into clinical stage development. This therapy utilizes a novel systemic treatment delivery method to target common KRAS-driven cancers with substantial medical needs. This milestone highlights the potential impact of this innovative approach in addressing prevalent cancer types.